The Impact of WHO Essential Medicines Policies on Inappropriate Use of Antibiotics

Kathleen Anne Holloway1*, Laura Rosella2, David Henry2

1 Department of Health Systems Development, World Health Organization, Regional Office South East Asia, New Delhi, India, 2 Epidemiology Division, Dalla Lana School of Public Health, The University of Toronto, Toronto, Canada

* kaholloway54@gmail.com

Abstract

Background
Inappropriate overuse of antibiotics contributes to antimicrobial resistance (AMR), yet policy implementation to reduce inappropriate antibiotic use is poor in low and middle-income countries.

Aims
To determine whether public sector inappropriate antibiotic use is lower in countries reporting implementation of selected essential medicines policies.

Materials and Methods
Results from independently conducted antibiotic use surveys in countries that did, and did not report implementation of policies to reduce inappropriate antibiotic prescribing, were compared. Survey data on four validated indicators of inappropriate antibiotic use and 16 self-reported policy implementation variables from WHO databases were extracted. The average difference for indicators between countries reporting versus not reporting implementation of specific policies was calculated. For 16 selected policies we regressed the four antibiotic use variables on the numbers of policies the countries reported implementing.

Results
Data were available for 55 countries. Of 16 policies studied, four (having a national Ministry of Health unit on promoting rational use of medicines, a national drug information centre and provincial and hospital drugs and therapeutics committees) were associated with statistically significant reductions in antibiotic use of ≥20% in upper respiratory infection (URTI). A national strategy to contain antibiotic resistance was associated with a 30% reduction in use of antibiotics in acute diarrheal illness. Policies seemed to be associated with greater effects in antibiotic use for URTI and diarrhea compared with antibiotic use in all patients. There were negative correlations between the numbers of policies reported implemented and the percentage of acute diarrhoea cases treated with antibiotics (r = -0.484, p = 0.007) and the percentage of URTI cases treated with antibiotics (r = -0.472, p = 0.005). Major
study limitations were the reliance on self-reported policy implementation data and antibiotic use data from limited surveys.

Conclusions
Selected essential medicines policies were associated with lower antibiotic use in low and middle income countries.

Introduction
Antibiotic drug resistance is a serious global public health problem with high human and financial costs.[1–6] Inappropriate and over use of antibiotic drugs is widespread and contributes to rapidly increasing bacterial resistance.[7,8]

Policy-relevant interventions to combat inappropriate medicines use have generally had small effects.[9] In the case of antibiotic drugs this may be because the determinants of use, particularly in developing countries, have not been sufficiently understood or addressed.[10] The World Health Organisation (WHO) has long advocated for introduction of essential medicines policies to encourage rational use of medicines.[11, 12] These include specific measures to promote prudent use of antibiotic drugs to minimize the development of resistance.[13–15] However, implementation of policies in many low and middle-income countries is suboptimal with less than half of countries implementing many recommended policies.[16, 17]

In Europe, coordinated medicine policy implementation resulted in reduced inappropriate antibiotic use [18–20], but there is less evidence of policy impact in developing countries. [21] There is emerging evidence from analyses of WHO databases that some policies aimed at improving use of medicines generally are associated with more rational use and that the impact increases with the numbers of policies that are implemented at country level. [22]

The aim of this study was to perform further analyses of the WHO databases to determine if inappropriate antibiotic use in the public sector is less in low and middle-income countries that report implementing essential medicines policies than in those that do not.

Materials and Methods
Our overall methods have been described in detail previously.[22] In the previous study we evaluated a full range of policy options and a broad set of medicines use indicators. Here we focused on policies that are most relevant to prescribing of antibiotics and selected specific antibiotic use indicators. The study was limited to the public sector due to the lack of medicines use data in the private sector. We did not have access to time series data that would enable longitudinal analysis of policy impacts.

A dataset of antibiotic use (outcome) and reported policy implementation (exposure), with one set of policy implementation data and antibiotic use for each country, was created from two WHO databases. Public sector antibiotic use data for 2002–8, by country, were extracted from the WHO medicines use database.[7, 23, 24] The database contains information on medicines use in primary care in developing and transitional countries extracted from survey reports. We included only survey reports that described use of recommended validated measures of medicines use estimated from at least 600 prescriptions and/or three or more facilities. [25, 26] Policy implementation data were extracted from WHO policy databases of questionnaires sent to Ministries of Health in 2003 and 2007.[16, 17] In these surveys, questions on pharmaceutical policy and regulation are asked in a standard format [27].
Variables

We excluded policies that had previously been shown to have no effect on overall medicines use, and overlapping policies, as described previously.[22] Of the remainder we selected policies that we considered most relevant to antibiotic use. In doing this we were guided by the WHO Global Strategy for Containment of Antimicrobial Resistance (AMR) and the WHO Global Action plan on AMR.[13, 28, 29] Those policies that best captured recommended strategies to reduce inappropriate antibiotic use and contain AMR were selected.[13, 28, 29] In this way, 16 policies were evaluated. They are listed in Table 1.

We chose four outcome variables [25, 26]:

- % of primary care cases receiving antibiotics. This gives some indication of overall antibiotic use
- % of upper respiratory tract infection cases that received antibiotics (high values signify over-use)
- % acute diarrhea cases that received antibiotics (high values signify over-use)
- % cases not needing antibiotics that received antibiotics (inappropriate use)

As national wealth has been shown to correlate with policy implementation and quality use of medicines economic status was considered a potential confounder. Gross National Income per capita (GNI per capita) in 2009/2010 for countries was extracted from the World Bank data-base http://data.worldbank.org/indicator/NY.GDP.PCAP.CD and used to stratify some analyses (see below).

Analyses

Univariate analysis was used to estimate the differences in average scores (as proportions reporting the outcome) for each of the four antibiotic use indicators between countries that did or did not report implementation of the 16 individual policies. Each policy was the unit of analysis and for each of these indicators a lower score equated with better use. The sample sizes were too small to enable direct comparisons of different policy impacts, so the effect sizes reported here cannot be used to make inferences about relative effectiveness of the policies we evaluated. Consequently, we did not adjust the P values for multiple testing. To look at the impact of multiple policies we regressed the scores for each of the 4 outcome measures on the number (out of 16) of policies countries reported implementing. Because of missing data we had to adjust the estimated numbers of implemented policies using the formula: adjusted policy number = (number of policies reported / (16—missing values for policies)) * 16.[22] In these analyses each country was the unit of analysis. We examined the impact of national wealth by performing separate regressions of outcomes on policy numbers separately for countries above and below the median value for gross national income per capita (GNIpc). All analyses were done in Stats Direct (version 2.7.9) and SAS (version 9.4).

Results

From the WHO database, 55 countries had analysable data on policies and antibiotic use. Out of a possible 880 policy responses (16 policies in each of 55 countries), 718 (82%) were available for analysis.

Comparison of Antibiotic Use Indicators in Countries With and Without Specific Policies

Table 1 shows the differences between countries that did or did not report implementation of specific policies for the four antibiotic indicators. The effect sizes associated with various
Table 1. Differences in antibiotic use between countries with and without each of 16 policies hypothesized to decrease inappropriate antibiotic use.

| National medicines policies and strategies (numbers in parenthesis refer to the number of countries contributing data to each analysis) | % of primary care cases receiving antibiotics | % of upper respiratory infection cases given ABs | % of acute diarrhea cases that received antibiotics | % of cases not needing antibiotics that received them (inappropriate use) |
|---|---|---|---|---|
| **National policies** | | | | |
| 1 National strategy to contain antibiotic resistance (n = 35, 25, 23, 18) | -3.4 | -15.3* | -30.7* | -2.7 |
| **Educational policies** | | | | |
| 2 Undergraduate training of doctors on the Standard Treatment Guidelines (n = 28, 21, 20, 17) | -4.1 | -17.9 | -13.5 | -7.5 |
| 3 Undergraduate training of nurses on the Standard Treatment Guidelines (n = 27, 20, 20, 16) | -1.9 | -14.3 | -5.8 | -7.0 |
| 4 Public education on antibiotics in last 2 years (n = 38, 28, 27, 17) | -1.1 | -19.5 | -8.8 | -4.0 |
| **Managerial Policies** | | | | |
| 5 National Essential Medicines List updated in the last 2 years (n = 32, 24, 23, 17) | -3.9 | -8.6 | -3.7 | -7.6 |
| 6 National Formulary updated in the last 5 years (n = 43, 31, 28, 22) | -4.8 | -11.9 | -4.9 | -2.4 |
| **Economic Policies** | | | | |
| 7 No Drug sales revenue used to supplement prescriber income* (n = 40, 29, 28, 20) | -2.6 | -7.6 | -13.7* | -11.9 |
| 8 Drugs dispensed free of charge to all patients (n = 40, 29, 26, 20) | -6.4 | -12.5 | -18.8* | -19.7 |
| 9 Drugs dispensed free of charge to patients < 5 years (n = 38, 28, 24, 18) | -4.5 | -11.3 | -10.0 | -13.5 |
| **Regulatory policies** | | | | |
| 10 Antibiotics not available over-the-counter* (n = 41, 30, 28, 21) | -1.8 | +2.2 | -12.1 | -11.3 |
| 11 Joint regulation of drug promotion by government and industry (as opposed to regulation by government alone) (n = 40, 29, 27, 21) | -2.0 | -5.0 | -3.0 | -13.0 |
| **Administrative/Structural policies** | | | | |
| 12 National MOH unit on promoting rational use of medicines (n = 35, 26, 25, 21) | -5.1 | -22.2* | -18.1* | +4.2 |
| 13 Half or more of all general hospitals have a Drug and Therapeutic Committee* (n = 36, 26, 25, 18) | -0.9 | -25.3* | -1.4 | -7.1 |
| 14 Half or more of all provinces/districts have a Drug and Therapeutic Committee* (n = 35, 25, 23, 19) | -8.2 | -21.2 | -0.5 | -1.4 |
| 15 Presence of National Drug Information Centre (n = 37, 27, 24, 21) | -10.2 | -25.1* | -6.9 | -8.5 |
| **Human resource policies** | | | | |
| 16 No prescribing by staff with less than one month's training in public primary care* (n = 35, 25, 24, 17) | -2.6 | -3.1 | -5.4 | +0.1 |

^ Graded response converted to a “yes/no” response.

* p < 0.05. Note: these P values are not corrected for multiple testing and are presented here to help identify patterns in the data not to test hypotheses regarding the relative effectiveness of the different policies.

doi:10.1371/journal.pone.0152020.t001
Policies were generally larger when measured by the two ‘condition-specific’ indicators (inappropriate use of antibiotics in upper respiratory tract infection and diarrhea) than when measured by the % patients receiving antibiotics or % of cases not needing antibiotics who received them.

Policies associated with statistically significant 20% or greater reductions in use of antibiotics in one or more of 4 settings described in the outcome indicators were: having a MOH department to promote rational use of medicines, having a national Drug Information Centre, and having drug and therapeutic committees in more than half of all general hospitals and more than half of all provinces. Several of the other policies were associated with lower use of antibiotics across all indicators, though the effects were smaller. Only 2 of 64 comparisons were associated with increased antibiotic use and the effects were small (2 and 4% respectively).

**Effects of Multiple Policies and Impact of National Wealth**

There were statistically significant, moderate, negative correlations between the reported number of medicines policies implemented (out of 16) and the percentage of acute diarrhoea cases treated with antibiotics (Fig 1) and the percentage of upper respiratory tract infection cases treated with antibiotics (Fig 2). There were statistically non-significant correlations between the reported number of medicines policies implemented and the percentage of patients not needing antibiotics who received them (Fig 3) and the percentage of all patients treated with antibiotics (Fig 4).

We examined the effects of national wealth measures on these correlations. In the case of diarrheal disease, the negative correlation between numbers of policies and antibiotic use was stronger in countries below the median GNIpc ($1365) ($r = -0.5860, P < 0.022$) than in countries above the median ($r = -0.4821, P < 0.067$). However, this pattern was not seen with upper respiratory infection, where the negative correlation between policy numbers and antibiotic use was
stronger in countries with GNIpc values above the median \( (r = -0.6008, P = 0.014) \) than in countries with wealth levels below the median \( (r = -0.3407, P = 0.181) \).

Fig 2. Correlation between the number of implemented policies (out of 16) and the treatment of acute upper respiratory tract infection with antibiotics. Correlation coefficient \( (r) = -0.472, p = 0.0053 \). Each data point (circle) represents a country.

doi:10.1371/journal.pone.0152020.g002

Fig 3. Correlation between the number of implemented policies (out of 16) and the percentage of patients not needing antibiotics who received them. Correlation coefficient \( (r) = -0.302, p = 0.1707 \). Each data point (circle) represents a country.

doi:10.1371/journal.pone.0152020.g003
A number of policies aimed at improving antibiotic use, as recommended by the WHO Global Strategy to Contain Antibiotic Resistance (AMR) and the Global Action Plan on AMR, were associated with reduced inappropriate use of antibiotics. Policies with the most clear-cut effects were: having a MOH department dedicated to promoting rational use of medicines, having a national strategy to contain antimicrobial resistance, having a national drug information centre and having drug and therapeutic committees in hospitals and provinces. Of 64 possible comparisons of single policy effects 24 were associated with reductions in antibiotic use of 10% or more.

Effect sizes for the two condition-specific indicators of antibiotic prescribing quality (in diarrheal disease and upper respiratory infection) were greater than the effect size for the “general” indicator of antibiotic usage. These were negative correlations and the weaker association for the general indicator may be because lower use is not always better in all patients, in contrast to the specific situations of upper respiratory infection and diarrheal disease.

Countries that reported implementing more of the selected policies had lower antibiotic use, particularly in the case of upper respiratory infection and in diarrheal disease. We found that this negative correlation was stronger in low income countries in the case of diarrheal disease but this trend was not seen for URTI. This may indicate genuine differences in the two different disease settings. Diarrheal disease has been a prominent target of public health campaigns in low income countries, including promotion of oral rehydration solutions, rather than antibiotics. Alternatively, the apparent differences may be due to the play of chance because of relatively small sample sizes. Previously, when we analysed the impact of national wealth on the impacts of multiple policies on composite measures of medicines use in a larger number of countries the effects were consistently greater in low income countries.[22]
Higher socio-economic status has been previously reported to be associated with better prescribing quality \[7–9, 22–24\] and increased policy implementation. \[16, 17, 22\] Increased economic status may improve and lower antibiotic use through having healthier populations and better health systems or by making it easier to implement policies to promote better use.

The majority of interventions, described in the literature, to improve antibiotic use in primary care are educational in nature, and many have been shown to be effective in producing short-term improvements in antibiotic use.\[9, 23, 24\] In this study, undergraduate education of doctors and nurses on standard treatment guidelines and public education on antibiotic use were associated with lower antibiotic use in diarrheal disease and upper respiratory infection. Likewise, public education campaigns in Europe have also been effective.\[18\]

Administrative policies, such as a dedicated MOH department to promote rational use of medicines, having drugs and therapeutic committees in hospitals and a national drug information centre, were also associated with significantly better quality of antibiotic prescribing in our study as was the provision of free essential medicines. Administrative and managerial strategies to support decision-making have been found effective elsewhere in improving antibiotic use.\[30–32\] A national MOH unit dedicated to promoting rational use of medicines was associated with improved use in Oman\[33\], and drug and therapeutic committees with improved guideline compliance in Laos.\[34\]

Other policies associated with better and lower antibiotic prescribing included no over-the-counter antibiotic availability, no prescriber income from antibiotic sales, no unqualified prescribers, and joint regulation by government and industry of drug promotion. Enforcement of non-availability of antibiotics over-the-counter was associated with decreased antibiotic use in Chile \[35\] and reduction of prescriber income from medicine sales, through separation of prescriber-dispenser function, was associated with reduced inappropriate antibiotic use in Korea. \[36\] Prescriber income from medicine sales associated with worse medicines use has been seen in Zimbabwe and China respectively.\[37, 38\] Joint government and industry regulation has been found to be associated with better overall medicines use compared to government regulation alone.\[22\]

Interventions that aim to appropriately increase antibiotic use in particular settings have resulted in large improvements of 15–25\%, such as training community members to diagnose and treat childhood pneumonia cases with antibiotics in Nepal. \[39\] However, interventions that aim to decrease antibiotics use appear to generate more modest improvements–as happened in Malaysia where academic detailing resulted in 11\% reduction in antibiotic use for upper respiratory tract infection.\[40\] The effect sizes on antibiotic prescribing quality of many of the individual policies examined in this study were modest. However, the overall effect size of multiple policies on the quality of antibiotic use in the treatment of acute diarrhoea and acute respiratory tract infection was large and comparable with the largest intervention effects reported elsewhere.\[8, 23\] A greater effect size with multiple interventions, as compared to a single intervention, has been described in several literature reviews.\[8–9, 23, 41–42\]

In our view the policies we have highlighted in these analyses reported here represent a blueprint for a national strategy to promote rational use of antibiotics–a critical component in the fight to contain anti-microbial resistance.

Limitations

We relied on self-reported information on policy implementation. Causality cannot be ascribed to the associations we have highlighted and we cannot be confident that effects associated with one policy are not due to another policy co-intervention. The small sample sizes prevented multi-variable analyses. But these limitations apply to the whole field. In the absence of
carefully collected longitudinal data at national level it is not possible to perform time series analysis, which represents a gold standard in policy evaluation.

We acknowledge that a multiple correction adjustment, such as Bonferroni, would render some of our findings statistically insignificant. However, our intention was not to test multiple hypotheses, particularly regarding the relative impact of the different policies. Our emphasis here is in identifying patterns in the data rather than emphasising statistical significance. The data themselves have serious limitations, which we address below. Nevertheless, they are the only comprehensive data available to address these important questions. The largest estimated policy effects were seen with the disease-specific antibiotic use measures (diarrheal disease and upper respiratory infections), and the strongest correlations with numbers of implemented policies were also seen for these outcomes. Taken together these suggest that our overall findings are quite robust.

We have previously documented other limitations of the data-sets used here.[22] Briefly, policies reported as implemented by MOHs may not have been implemented. The antibiotic use survey data for countries may not be generalizable, having come from individual published surveys although care was taken only to include surveys that followed minimum standards. [25] However, misclassification of policy implementation and inaccurate antibiotic use data would tend to weaken correlations seen between policy and antibiotic use. We were concerned that some countries that implemented multiple policies would feel under pressure to report better and lower antibiotic use. However, data on policy implementation came from MOHs and antibiotic use data from independently conducted surveys which reduces but does not eliminate the chance of biased reporting. Results were confined to the public sector due to lack of antibiotic use data in the private sector. Nevertheless, many of the policies may spill over into the private sector as doctors in low and middle income countries often have both public and private practices. We recognise our dependence on rather old data. We addressed this in our previous report.[22] In our view the findings here still have relevance as the essential medicines policy landscape has changed little in the last 10 years and the policies studied here are still recommended for widespread use.

We also need to consider the potential adverse effects of the policies designed to reduce dependence on antibiotics. It is possible that when policies target and reduce one particular antibiotic prescribing behaviour, another inappropriate behaviour is substituted. For example, increased antibiotic consumption has occurred after campaigns to reduce injection use.[43] Thus, it could be that reduction of antibiotic use for upper respiratory tract infection and acute diarrhoea could be accompanied by increased antibiotic use for other conditions or doctors simply changing the diagnoses to justify continued prescribing of an antibiotic. This may account for the lack of effect of policies on the overall use of antibiotics.

Our findings should be interpreted with a degree of caution. It may be that countries with more functional and efficient health systems are more likely to implement policies to promote better quality use of antibiotics. Better quality of antibiotic use was found in countries with higher economic status and this may be because of healthier populations, better health systems and/or more policy implementation

Conclusions

This is the first study to evaluate the impact of essential medicines policies recommended in the WHO Global Strategy to contain AMR and the WHO Global Action Plan 2015 on antibiotic use in multiple countries. The study shows in detail how different policies and numbers of policies impact on different indicators of antibiotic usage. The findings confirm that countries implementing these policies have less inappropriate use of antibiotics. This finding is
important in the fight to contain anti-microbial resistance. It is critical that much more international attention is focused on implementing essential medicine policies to reduce antibiotic use in low and middle income countries.

Disclaimer

Kathleen Anne Holloway is a staff member of the World Health Organization. The authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions or policies of the World Health Organization.

Supporting Information

S1 Table. Reported antibiotic policy implementation by country.
(XLSX)

S2 Table. Individual antibiotic use measures by country plus references.
(XLS)

Author Contributions

Conceived and designed the experiments: KAH. Performed the experiments: KAH. Analyzed the data: KAH LR DH. Contributed reagents/materials/analysis tools: KAH LR DH. Wrote the paper: KAH DH.

References

1. Levy SB. Antibiotic resistance: the problem intensifies. Adv. Drug Deliv. Rev. 2005; 57:1446–50. PMID: 15949867
2. Livermore DM. Bacterial resistance: origins, epidemiology, and impact. Clin. Infect. Dis. 2003; 36 (suppl 1): S11–23. PMID: 12516026
3. Harbarth S, Samore MH. Antibiotic resistance determinants and future control. Emerg. Infect. Dis. 2005; 11: 794–801e. PMID: 15963271
4. SCORE. Resistance: a sensitive issue, the European roadmap to combat antibiotic resistance. Strategic Council on Resistance in Europe, Utrecht, the Netherlands. 2004.
5. Institute of Medicine. Microbial threats to health: emergence, detection and response. Washington DC, National Academics Press. 1998.
6. Shorr AF. Epidemiology and economic impact of methicillin-resistance staphylococcus aureus: review and analysis of the literature. Pharmacoeconomics 2007; 25: 751–68. PMID: 17803334
7. WHO. Medicine use in primary health care in developing and transitional countries: factbook summarising results from studies reported between 1990 and 2006, WHO/EMP/MAR/2009.3, World Health Organisation, Geneva, 2009.
8. Holloway KA, van Dijk L, The World Medicines Situation 2011 (Third Edition), Rational Use of Medicines. WHO/EMP/MIE/2011.2.2. World Health Organization, Geneva, Switzerland. 2011. Available: http://www.who.int/medicines/areas/policy/world_medicines_situation/en/index.html.
9. Holloway KA. Combating inappropriate use of medicines, Expert Review Clinical Pharmacology, 2011; 4(3): 335–348.
10. Radyowijati A and Haak H. Improving antibiotic use in low-income countries: an overview of evidence on determinants. Soc. Sci.e Med. 2003; 57: 733–744.
11. WHO. The rational use of drugs. Report of the conference of experts. World Health Organisation, Geneva, 1985.
12. WHO. Promoting rational use of medicines: core components, WHO Policy Perspectives of Medicines, no.5, World Health Organisation, Geneva, 2002.
13. WHO. WHO Global Strategy for containment of antibiotic resistance. WHO/CSR/DRS/2001.2, World Health Organisation, Geneva, 2001.
14. WHO. Containing antibiotic resistance; Policy Perspectives on Medicines no.10, WHO/PSM/2005.1, World Health Organisation, Geneva, 2005.
15. Okeke IN, Klugman KP, Bhutta ZA, Duse AG, Jenkins P, O’Brien TF, et al. Antibiotic resistance in developing countries. Part II: strategies for containment. Lancet Infect Dis. 2005; 5(9): 568–580.

16. WHO. Using indicators to measure country pharmaceutical situations: Fact Book on WHO Level I and Level II monitoring indicators, WHO/TCM/2006.2, World Health Organisation, Geneva, 2006.

17. WHO. Country pharmaceutical situations: Fact Book on WHO Level 1 indicators 2007, WHO/EMP/ MPC/2010.1. World Health Organisation, Geneva, 2010.

18. Huittner B, Goossens H, Verheij T, Harbath S; for the CHAMP Consortium. Characteristics and outcomes of public campaigns with the aim to improve outpatient antibiotic use in high income countries. Lancet Infect. Dis. 2009; 10(1): 17–31.

19. Molstad S, Erntell M, Hanberger H, Melander E, Norman C, Skoog G, et al. Sustained reduction of antibiotic use and low bacterial resistance: 10 year follow-up of the Swedish STRAMPA programme. Lancet Infect. Dis. 2008; 8(2), 125–132. doi: 10.1016/S1473-3099(08)70017-3 PMID: 1822163

20. Sabuncu E, David J, Bernède-Bauduin C, Pépin S, Leroy M, Boelle P-Y, et al. Significant Reduction of Antibiotic Use in the Community after a Nationwide Campaign in France, 2002–2007. PLoS Med. 2009; 6(6): e1000084.

21. Ratanawijitrasin S, Soumerai SB, Weerasuriya K. Do national medicinal drug policies and essential drug programs improve drug use? A review of experiences in developing countries. Soc. Sci. Med. 2001; 53(7): 831–844. PMID: 11522132

22. Holloway KA, Henry D. WHO Essential Medicines Policies and Use in Developing and Transitional Countries: An Analysis of Reported Policy Implementation and Medicines Use Surveys. PLoS Med. 2014; 11(9): e1001724. doi: 10.1371/journal.pmed.1001724 PMID: 25226527

23. Holloway KA, Ivanovska V, Wagner AK, Vialle-Valentin C, Ross-Degnan D. Have we improved use of medicines in developing and transitional countries and do we know how to? Two decades of evidence. Tropical Medicine & International Health, 2013 18(6): 656–664.

24. Holloway KA, Ivanovska I, Wagner AK, Vialle-Valentin C, Ross-Degnan R. Prescribing for acute childhood infections in developing and transitional countries, 1990–2009. Paediatrics and International Child Health, 2015; 35(1): 5–13. doi: 10.1179/2046905514Y.0000000115 PMID: 24621245

25. World Health Organisation. How to investigate drug use in health facilities: selected use indicators. WHO/DAP/93.1. World Health Organisation, Geneva, 1993.

26. Gove S (1997). Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO Working Group on Guidelines for Integrated Management of the Sick Child. Bulletin of WHO, 1997; 75(Suppl 1): 7–24.

27. World Health Organisation. WHO Operational package for assessing, monitoring and evaluating country pharmaceutical situations: Guide for coordinators and data collectors. WHO/TCM/2007.2. World Health Organisation, Geneva, 2007.

28. WHO. Global Action plan on antibiotic resistance. Secretariat’s report A68/20. Available: http://apps.who.int/ebwha/pdf_files/WHA68/A68_20-en.pdf. Accessed 6.8.2015. World Health Organisation, Geneva, 2015.

29. WHO. Global Action plan on antibiotic resistance. Resolution WH68.17. Accessed: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_20_en.pdf. Accessed 6.8.2015. World Health Organisation, Geneva, 2015.

30. Lu CY, Ross-Degnan D, Sounerai SB, Pearson SA. Interventions designed to improve the quality and efficiency of medication use in managed care: a critical review of the literature – 2001–2007. BMC Health Services Research, 2008; 8: 75. doi: 10.1186/1472-6963-8-75 PMID: 18394200

31. Parrino TA. Controlled trials to improve antibiotic utilization: a systematic review of experience, 1984–2004. Pharmacotherapy, 2005; 25(2): 289–298. PMID: 15767243

32. Rowe AK, Onikpo F, Lama M, Osterholt DM, Rowe SY, Deming MS. A multifaceted intervention to improve health worker adherence to Integrated Management of Childhood Illness guidelines in Benin. American Journal of Public Health, 2009; 99(5): 837–846. doi: 10.2105/AJPH.2008.134411 PMID: 19299681

33. Jaffer B (2007). National approach of promote rational use of medicines: the Omani experience. WHO/NGO Technical Briefing Seminar, World Health Assembly, 14th May, Geneva. Directorate of Rational Drug Use Department, MOH, Oman. Available: http://www.who.int/drugresistance/OmanDRUDforWHAMeetingGeneva.pdf. Accessed 13 August 2015.

34. Vang C, Tomson G, Kounnavong S, Southammavong T, Phanyanouvong A, Johansson R, et al., Improving the performance of Drug and Therapeutics Committees in hospitals—a quasi-experimental study in Laos. Eur J Clin Pharmacol. 2006; 62:57–63. PMID: 16372173

35. Bavestrello L, Cabello A, Casanova D. Impact of regulatory measures in the trends of community consumption of antibiotics in Chile. Rev. Med. Chil. 2002; 130(11): 1265–1272. PMID: 12587509
36. Park S, Soumerai SB, Adams AS, Finkelstein JA, Jang S, Ross-Degnan D. Antibiotic use following a Korean national policy to prohibit medication dispensing by physicians. Health Policy Plan. 2005; 20 (5): 302–309. PMID: 16000369

37. Trap B, Hansen EH, Hogerzeil HV. Prescription habits of dispensing and non-dispensing doctors in Zimbabwe. Health Policy Plan. 2002; 17(3):288–295. PMID: 12135995

38. Chen W, Tang S, Sun J, Ross-Degnan D, Wagner A. Availability and use of essential medicines in China: manufacturing, supply and prescribing in Shandong and Gansu provinces. BMC Health Services Research, 2010; 10: 211. doi: 10.1186/1472-6963-10-211 PMID: 20637116

39. Holloway KA, Karkee S, Tamang A, Gurung Y, Pradhan R, Reeves B. Community intervention to promote rational treatment of acute respiratory tract infection in rural Nepal. Tropical Medicine and International Health, 2009; 14(1): pp.1–10.

40. Teng CL, Achike FI, Phua KL, Nurjahan MI, Mastura I, Nor Asiah H, et al. Modifying antibiotic prescribing: the effectiveness of academic detailing plus information leaflet in a Malaysian primary care setting. Med J Malaysia 2006, 61(3): 323–331. PMID: 17240584

41. Francke AL, Smit MC, De Veer AJE, Mistiaen P. Factors influencing the implementation of clinical guidelines for health care professionals: a meta-review. BMC Med. Inform. Decis. Mak. 2008; 8: 38. doi: 10.1186/1472-6947-8-38 PMID: 18789150

42. Sketris IS, Ingram EML, Lummis HL. Strategic opportunities for effective optimal prescribing and medication management. Can. J. Clin. Pharmacol. 2009; 16(1): e103–e125. PMID: 19182305

43. Logan S, Hutin Y, Somda P, Thuault J, Holloway K. Safer injections following a new national medicine policy in the public sector, Burkina Faso 1995–2000. BMC Public Health 2005; 5: 136. PMID: 16364178